AI MLR Review for Pharma: What AI Can Check, What to Buy and How to Pilot It

What AI MLR review actually does

AI MLR review uses language models to check pharma promotional and medical content before, and alongside, the medical, legal and regulatory reviewers. In practice it does three jobs well today: it extracts every claim in a piece and matches it to a reference, it flags missing or mismatched safety information and required statements, and it checks brand, editorial and channel rules. It does not approve content. A named human reviewer still signs off, and the AI's job is to make sure what reaches that reviewer is cleaner, so fewer rounds are needed.

That framing matters because most of the time lost in MLR is not the review itself. It is the back and forth: a claim without a reference, an outdated ISI, a dosing statement that does not match the label, a footnote in the wrong place. Each one sends the piece back to the agency and adds another cycle. AI pre-review catches that class of error before submission, which is why vendors and early adopters measure success in first-pass approval rate and rounds per piece rather than in reviewer headcount.

This guide is for content operations, commercial and compliance leaders at pharma and biotech companies deciding whether to buy, build or wait. It covers what AI can safely check, the three ways to get it, how to run a pilot that produces a real answer, the audit trail your reviewers will insist on, and when not to buy anything yet. We build AI agents and data workflows for life sciences teams; we are not a law firm, so confirm regulatory positions with your own counsel.

Where AI in MLR stands at the end of 2026

Why MLR review automation is on the agenda now

Two pressures meet in the MLR queue. The first is volume. Omnichannel programmes, modular content and market-by-market personalisation multiply the number of assets a brand needs, and every one of them still goes through the same review committee. If you have read our guide to pharma omnichannel analytics, you will know how quickly the channel count grows once a brand moves beyond the rep and the website.

The second is scrutiny. On 9 September 2025 FDA announced a broad enforcement initiative on direct-to-consumer promotion and then posted a wave of untitled and warning letters. Manatt's summary of the letters released on 16 September 2025 lists the recurring themes: imagery that implies a better quality of life than patients can typically expect, and major statements of risk presented in a way that visuals and fast scene changes distract from. Those are exactly the issues reviewers are now told to look harder for, which makes every review round slower at the same time as the queue grows.

The answer most companies are testing is not fewer reviewers. It is better submissions. When the agency or brand team runs an AI pre-check before routing a piece, the reviewer spends time on judgement calls rather than on missing references and template errors. That is the realistic promise of AI in MLR, and it is also the right way to scope a business case: measure rework avoided, not people replaced.

What AI can check in MLR, and what must stay human

Safe to automate

These checks have a clear right answer that can be found in an approved source document. They are the best place to start because errors are easy to verify and the reviewer can see exactly why something was flagged.

AI assists, human decides

Here the model can point at a likely problem, but the decision depends on context, precedent and the company's own risk appetite. Treat the output as a prompt for the reviewer, never as a pass or fail.

Keep human

Final approval, regulatory strategy and anything that depends on judgement about intent stays with named reviewers. A tool that offers to auto-approve low-risk pieces should be treated with caution until your legal and regulatory leads have agreed the boundary in writing.

Three ways to get AI MLR review, and when each fits

• Platform-native AI

  If your content already runs through Veeva Vault PromoMats, its AI agents work inside the documents and workflow your reviewers know. Quick Check scans against editorial, brand, market, channel and compliance guidelines; Content Agent summarises and answers questions about a piece.

  • Best fit: companies already standardised on PromoMats
  • Least change for reviewers
  • You are limited to the checks the vendor ships

• Specialist pre-check tools

  A group of vendors sells AI pre-review that sits in front of, or plugs into, the review platform. IntuitionLabs' 2026 roundup of MLR review software covers Papercurve, SecureCHEK AI, Revisto and EVERSANA ORCHESTRATE MLR among others. None publishes list pricing.

  • Best fit: agencies and brands wanting checks before routing
  • Check the integration with your review platform
  • Most performance figures are vendor-reported

• Custom pre-review agent

  A purpose-built agent, run in your own cloud tenant, that checks drafts against your claims library, current label and brand rules, then writes a structured report into the submission. This is the route for rules no product covers, or for content types outside the review platform.

  • Best fit: specific gaps, multiple platforms, strict data rules
  • You own the prompts, tests and logs
  • Needs ongoing evaluation as labels and rules change

How to choose: a short decision guide

Start from where your content lives and where your errors come from, not from the demo.

• If you are on PromoMats and most rework is template and reference errors, pilot the native agents first. The integration work is done, and the comparison you need is your own before and after numbers.
• If agencies create most of your content, the pre-check belongs on the agency side of the handoff. Look at tools that agencies can run before routing, and write the expectation into the agency brief: no piece is routed without a clean pre-check report attached.
• If your problem is a specific rule set, such as market-specific requirements, social character limits with ISI, or a claims library that lives outside the review platform, a narrow custom agent often costs less than a platform change. Our AI agent development work for regulated teams follows this pattern: one job, grounded in approved sources, every decision logged.
• If you cannot yet say how many rounds a typical piece takes, do not buy anything. Fix the measurement first, because without a baseline no vendor's claims can be tested against your reality.

Whichever route you pick, ask every vendor the same questions: which model runs the checks and where it is hosted, whether your content is used for training, how the tool shows the source for each flag, what happens when the label changes, and what the audit log contains. A vendor that cannot answer the last two clearly is not ready for a regulated workflow.

A six-step pilot that gives you a real answer

A worked example: putting a value on fewer review rounds

Vendor figures are a starting point at best, because they come from the vendors' own pilots. Build the business case on your numbers. The arithmetic below uses illustrative figures only, to show the method; replace every number with what your step one baseline shows.

Suppose a brand team routes 400 pieces a year, each piece averages 2.5 review rounds, and the baseline shows that 60 percent of send-backs were mechanical (missing references, outdated ISI, template errors). That is 400 × 1.5 = 600 extra rounds a year, of which about 360 were mechanical.

If the shadow pilot shows the AI would have caught half of those mechanical issues before submission, the team avoids about 180 rounds a year. Now price a round with your own inputs: reviewer hours per round across medical, legal and regulatory, agency rework hours, and the calendar days each round adds. If a round costs six reviewer hours and four agency hours, 180 rounds is 1,800 hours a year returned, plus the faster time to market for every piece that no longer waits for a second or third cycle.

Two cautions. First, the AI only creates value if creators act on the pre-check before routing; if they ignore the report, the number is zero. Second, count the cost of keeping it accurate: rules, claims library and label updates need an owner, and somebody has to review the evaluation results every quarter.

Audit trail and data requirements to write into any contract

Common mistakes, and when not to buy

The mistakes we see repeat across companies and tools:

• Buying before measuring. Without rounds per piece and rejection reasons, nobody can say whether the tool worked, and the renewal decision becomes a matter of opinion.
• Starting with judgement checks. Fair balance and implied claims are where reviewers are least willing to trust a model. Start with references and required elements, earn trust, then widen.
• Putting the AI after submission. If the check runs inside the review step, reviewers do the same work plus read an AI report. The value comes from moving fixes upstream to the creator and the agency.
• Treating vendor percentages as forecasts. Figures like 86 percent fewer errors come from vendor pilots on their own terms. Your result depends on your content mix and your current error rate.
• No owner for the rules. A pre-check that runs against last quarter's label is worse than none, because it produces false confidence.

Do not buy yet if your content volume is low enough that reviewers are not the bottleneck, if your claims library and references are not in a usable digital form, or if you are about to change review platforms. In those cases the better first project is the data underneath: a clean claims library, a current reference set, and reporting on review cycle data. For the wider picture of where AI pays off in commercial and medical teams, see our guides to AI tools for the life sciences industry and AI tools for medical affairs teams.

Questions about AI MLR review